Table 1.
Clinical characteristics at presentation, treatment, and response of 939 patients with classical Hodgkin lymphoma.
| Number [N = 939] | Percent [%] | |
|---|---|---|
| Age Median (range) | 38 years (18–99) | |
| <50 | 664 | 70.71% |
| ≥50 | 275 | 29.29% |
| Gender: ratio | 2.07:1 | |
| Male | 634 | 67.52% |
| Female | 305 | 32.48% |
| Stage | ||
| 1 | 107 | 11.40% |
| 2 | 331 | 35.25% |
| 3 | 274 | 29.18% |
| 4 | 227 | 24.17% |
| B symptoms | ||
| Absent | 465 | 49.57% |
| present | 473 | 50.43% |
| Missing | 1 | |
| Early-stage groups | ||
| Favorable | 57 | 13.04% |
| Unfavorable | 380 | 86.96% |
| Missing | 1 | |
| Late-stage IPI score | ||
| Low 0–3 | 336 | 70.29% |
| High 4–7 | 142 | 29.71% |
| Missing | 23 | |
| Comorbidities | ||
| None | 539 | 81.30% |
| 1 or more | 124 | 18.70% |
| Missing | 276 | |
| HL subtype | ||
| Mixed cellularity | 569 | 60.60% |
| Nodular sclerosis | 253 | 26.94% |
| Lymphocytic rich classical HL | 92 | 9.80% |
| Lymphocytic depleted classical HL | 25 | 2.66% |
| Treatment | ||
| ABVD | 889 | 94.68% |
| Others [COPP, AVD+/- etoposide] | 50 | 5.32% |
| Chemotherapy-RT | ||
| Chemo + RT | 197 | 21.00% |
| Chemo only | 741 | 79.00% |
| RT only | 1 | |
| Chemo cycles + RT | ||
| 4 cycles | 143 | 15.98% |
| 4 cycles + RT | 68 | 7.60% |
| 6 cycles | 557 | 62.23% |
| 6 cycles + RT | 127 | 14.19% |
| Chemo cycles in the early stage | ||
| 4 cycles | 149 | 35.14% |
| 6 cycles | 275 | 64.86% |
| Missing | 14 | |
| RT in the early stage | ||
| Yes | 130 | 29.68% |
| No | 308 | 70.32% |
| Response | ||
| Complete response | 743 | 80.67% |
| Partial response | 118 | 12.81% |
| Stable disease | 21 | 2.28% |
| Progression on treatment | 39 | 4.23% |
| Non-evaluable | 18 | |
| First relapse/progression | ||
| Early stage | 46 | 34.85% |
| Advanced stage | 86 | 65.15% |
RT, radiotherapy.